Newsroom | 11926 results
Sorted by: Latest
-
AIS Healthcare Awarded a Group Purchasing Agreement for 503A Intrathecal Compounded Medications with Premier, Inc.
DALLAS--(BUSINESS WIRE)--AIS Healthcare has been awarded a group purchasing agreement for 503A intrathecal compounded medications with Premier, Inc., effective July 1, 2025. The new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for sterile, patient-specific intrathecal pain pump medications. In addition, to assist with compliance policies, this agreement with Premier will provide member hospitals with site audit e...
-
BlinkRx Launches “Operation Access Now” to Accelerate and Scale Direct‑to‑Patient and Direct‑to‑Business Programs
NEW YORK--(BUSINESS WIRE)--BlinkRx, the nation's leading prescription lifecycle management platform, today announced the launch of Operation Access Now, a rapid deployment initiative that enables pharmaceutical manufacturers to build and launch direct-to-patient (DTP) and direct‑to‑business (DTB) channels that expand medication access and deliver pricing transparency in as little as 21 days. This program comes at a moment of growing urgency across the life sciences industry. As traditional acce...
-
Orpyx Launches Sensory Insole Program to Combat >$80B Annual Cost of Diabetic Foot Complications
CALGARY, Alberta--(BUSINESS WIRE)--Orpyx launches next-gen sensory insole program to prevent diabetic foot ulcers, reduce costs, and support value-based care through remote monitoring....
-
Insulet Reports Second Quarter 2025 Revenue Increase of 32.9% Year-Over-Year (31.3% Constant Currency1)
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended June 30, 2025. Second Quarter Financial Highlights: Revenue of $649.1 million, up 32.9%, or 31.3% in constant currency, exceeds the high end of the Company’s guidance range of 26.0% in constant currency Total Omnipod revenue of $639.0 million, up 33.0%, o...
-
Kenvue Reports Second Quarter 2025 Results
SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) today announced financial results for the second quarter ended June 29, 2025. “Kenvue has a strong portfolio of world-class, category-defining brands. We are actively focused on improving execution and performance, while advancing the comprehensive strategic alternatives review, to deliver our inherent value,” said Kirk Perry, Interim Chief Executive Officer. “I’m thrilled to take on this new role at such an important time for the Company...
-
Swisslog Healthcare Elevates Jennie McQuade to Global Chief Legal Counsel & Privacy Officer
BROOMFIELD, Colo.--(BUSINESS WIRE)--Swisslog Healthcare, a global leader in pharmacy and transport automation solutions, announces the promotion of Jennie McQuade to Global Chief Legal Counsel & Privacy Officer. This appointment recognizes McQuade's decade-long commitment to enhancing data security and privacy in the healthcare industry. "Jennie’s leadership has been instrumental in strengthening our security posture and navigating complex global privacy regulations.” said Cory Kwarta, CEO...
-
KORU Medical Systems Announces Q2 2025 Financial Results, Including Record Double-digit Revenue, and Raises 2025 Revenue Guidance
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the second quarter ended June 30, 2025. Financial Highlights • Second quarter 2025 net revenues of $10.2 million, a 21% increase over the prior year period • Core bus...
-
Cerus Corporation Announces Second Quarter 2025 Financial Results
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) announced financial results for the second quarter ended June 30, 2025, and provided a business update. “With our singular focus to advance blood safety and availability around the globe by establishing INTERCEPT as the standard of care, this quarter’s commercial results are evidence of the progress we are making in multiple geographies and across our INTERCEPT product portfolio. The early launch and adoption of our next generati...
-
New Data Show Better Outcomes for Hospitalized Surgical Patients
WASHINGTON--(BUSINESS WIRE)--Surgical patients had better outcomes in 2024 than they did in 2019, according to a new report by the American Hospital Association and Vizient....
-
AdaptHealth Corp. Announces Second Quarter 2025 Results
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, announced today financial results for the second quarter ended June 30, 2025. Second Quarter Results and Highlights All comparisons are to the quarter ended June 30, 2024 unless otherwise stated. Net revenue was $800.4 million compared to $806....